Introduction Neuroprotection remains a central challenge in the management of acute liver failure, where cerebral oedema and intracranial hypertension are major drivers of mortality. Traditionally, invasive intracranial pressure monitoring has been used to guide management, but recent shifts in clinical practice suggest a move away from this approach.
Introduction
Neuroprotection remains a central challenge in the management of acute liver failure, where cerebral oedema and intracranial hypertension are major drivers of mortality. Traditionally, invasive intracranial pressure monitoring has been used to guide management, but recent shifts in clinical practice suggest a move away from this approach. This evolving paradigm reflects a deeper understanding of the pathophysiology of brain injury in acute liver failure, where ammonia toxicity, systemic inflammation, and blood–brain barrier dysfunction act synergistically rather than independently.
Summary
This article highlights a significant transition in neuroprotective strategies in acute liver failure following evidence that declining use of invasive intracranial pressure monitoring has not adversely affected survival outcomes. The focus is shifting from reactive management of intracranial hypertension to proactive prevention of cerebral oedema. Blood ammonia is emphasised as a key early biomarker for identifying high-risk patients, although it is recognised as a downstream marker rather than the primary driver of injury. Increasing attention is being directed toward upstream mechanisms, particularly systemic inflammation and cytokine-mediated neurotoxicity, which may offer future therapeutic targets.
The second major shift is toward non-invasive, multimodal neurological monitoring. Emerging tools such as transcranial Doppler, near-infrared spectroscopy, and continuous electroencephalography offer dynamic insights into cerebral perfusion, oxygenation, and neuronal activity, enabling a more comprehensive and individualised assessment of brain function without procedural risk.
Finally, the reduction in invasive monitoring introduces a critical clinical challenge: determining irreversible brain injury and transplant eligibility. The author proposes a multimodal framework combining imaging, functional neurophysiology, and biomarkers to guide decision-making. This approach is essential to ensure appropriate use of liver transplantation while avoiding both futile interventions and missed opportunities for timely transplantation.
Introduction: Bacterial infections remain a major cause of morbidity after liver transplantation despite advances in perioperative care. Synbiotics, combining probiotics and prebiotics, have been proposed to reduce postoperative infections by restoring gut microbiota and strengthening...
Introduction: Perioperative bleeding remains a major challenge during orthotopic liver transplantation (OLT), largely due to hyperfibrinolysis and coagulation abnormalities. Although tranexamic acid (TXA) effectively reduces bleeding in several surgical settings, its routine prophylactic use during...
Introduction: Liver transplantation is limited by a shortage of suitable donor organs. Current viability assessment relies on needle biopsy, which samples only a small portion of the liver and may miss important regional pathology. This...
Introduction: Bleeding remains a major challenge during liver transplantation despite advances in surgical techniques, anesthesia, and perioperative care. Antifibrinolytic agents have long been used to reduce intraoperative blood loss and transfusion requirements. However, evolving transplant...
Introduction: The demand for liver transplantation continues to exceed the availability of deceased donor organs, resulting in prolonged waiting times and preventable waitlist mortality. This perspective discusses how living donor liver transplantation (LDLT) can complement...
Introduction: Pediatric liver transplantation has achieved excellent survival rates, shifting the focus from graft survival alone to optimising long-term health, growth, neurodevelopment, and quality of life. This updated guideline provides evidence-based recommendations for comprehensive care...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.